TidalSense

TidalSense, a Cambridge-based start-up, has successfully secured £14.2 million in a significant funding round to commercialise its innovative handheld device for rapid lung disease diagnosis.

Summary of transaction details:

• Value: £14.2 million
• Sector: Healthcare & Biotech
• Advisor: Not specified
• Key Entities: TidalSense (Target), Cross Border Impact Ventures (Lead Investor), BGF, Airstream Capital, Foresight Group (Returning Backers)
• Location: Cambridge, UK (Target)

Note: This funding round will enable TidalSense to expand the rollout of its AI-powered diagnostic test across the NHS, pursue commercial opportunities in Europe, and enter the US market, addressing the critical need for earlier and more efficient diagnosis of chronic obstructive pulmonary disease (COPD). The investment underscores a growing interest in defensible hardware-based solutions within the MedTech sector.